Abstract
Prevention and management of human cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation has improved substantially in the past decade. However, with this improvement, there is increased complexity in deciding which diagnostic tests, treatment strategies and immunologic assessments are optimal for different patient populations. The purpose of this review is to address certain practical problems that commonly arise and suggest a suitable approach to management that should have wide applicability.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Meyers JD, Fluornoy N, Thomas ED . Nonbacterial pneumonia after allogeneic marrow transplantation. A review of ten years experience Rev Infect Dis 1982 4: 1119 1132
Ljungman P, Aschan J, Lewensohn-Fuchs I et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients Transplantation 1998 66: 1330 1334
Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human marrow transplantation J Infect Dis 1986 153: 478 488
Boland GJ, Hene RJ, Ververs C et al. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation Clin Exp Immunol 1993 94: 306 312
Kroger N, Zabelina T, Kruger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin Br J Haematol 2001 113: 1060 1071
Verdonck LF, van den hoek MR, Rozenberg-Arska M et al. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants Clin Infect Dis 1997 24: 901 907
Mohty M, Faucher C, Vey N et al. High rate of secondary viral and bacterial infections in patients undergoing allogenic bone marrow mini-transplantation Bone Marrow Transplant 2000 26: 251 255
Hebart H, Brugger W, Grigoleit U et al. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality Blood 2001 97: 2183 2185
Bowden RA, Slichter SJ, Sayers MH . Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant Blood 1991 78: 246 250
Holmberg LA, Boeckh M, Hooper H et al. Increased incident of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation Blood 1999 94: 4029 4035
Peggs K, Ings SJ, Kottaridis PD et al. Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multible myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring Blood 2000 96: 369 370
Einsele B, Ehninger G, Hebart H . Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation Blood 1995 86: 2815 2820
Boeckh M . Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy Transplant Infect Dis 1999 1: 165 178
Gleaves CA, Smith TF, Shuster EA et al. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen J Clin Microbiol 1984 19: 917 991
Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients Blood 1999 93: 1781 1782
Boeckh M, Bowden RA, Zaia JA . Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture Transplantation 1997 64: 108 113
Hebart H, Wuchter P, Loeffler J et al. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogenic stem cell transplant Bone Marrow Transplant 2001 28: 213 218
Einsele H, Ehninger G, Steidle M . Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease Lancet 1991 2: 1170 1172
Compton J . Nucleic acid sequence-based amplification Nature 1991 350: 91 92
Slavin MA, Gooley TA, Bowden RA . Prediction of cytomegalovirus pneumonia after marrow transplantation from cellular characteristics and cytomegalovirus culture of bronchoalveolar lavage fluid Transplantation 1994 58: 915 919
Sakamaki H, Yuasa K, Goto H et al. Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation Bone Marrow Transplant 1997 20: 143 147
Schmidt GM, Horak DA, Niland JC . A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants New Engl J Med 1991 324: 1005 1110
Yun Z, Lewensohn-Fuchs I, Ljungman P et al. Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays Transplantation 2000 69: 1733 1736
Limaye AP, Huang ML, Leisenring W et al. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients J Infect Dis 2001 183: 377 382
Goodrich JM, Mori M, Gleaves CA . Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation New Engl J Med 1991 325: 1601 1607
Zaia JA, Schmidt GM, Nelson JC et al. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up Biol Blood Marrow Transplant 1995 1: 88 93
Goodrich JM, Bowden RA, Fisher L et al. Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis Ann Intern Med 1993 118: 173 178
Salzberger B, Boeckh M, Davis C . Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease risk factors and outcome Blood 1997 90: 2502 2508
Li C-R, Greenberg PD, Gilbert MF et al. Recovery of HLA-restricted cytomegalovirus (CMV) specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 1994 7: 1971 1997
Meyers JD, Reed EC, Shepp DH . Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation New Engl J Med 1988 318: 70 75
Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation Lancet 1994 343: 749 753
Reusser P, Gambertoglio JG, Lilleby K et al. Phase I–II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients J Infect Dis 1992 166: 473 479
Aschan J, Ringdén O, Ljungman P . Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients Scand J Infect Dis 1992 24: 143 150
Bacigalupo A, van Lint E, Tedone F . Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir Bone Marrow Transplant 1994 13: 753 758
Ljungman P, Öberg G, Aschan J . Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients Bone Marrow Transplant 1996 18: 565 568
Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation Blood 2001 97: 388 392
Boeckh M, Gooley TA, Myerson D . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 10: 4063 4071
Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants Lancet 2000 356: 645 649
Bacigalupo A, Bregante S, Tedone E . Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation Transplantation 1996 62: 376 380
Winston DJ, Ho WG, Bartoni K . Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients Ann Intern Med 1993 118: 179 184
Boeckh M, Zaia JA, Jung D et al. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation Biol Blood Marrow Transplant 1998 4: 13 19
Spielberger R, Zaia J, Nelson RA et al. Use of oral ganciclovir (PO-GCV) for the preemptive treatment (TX) of CMV following allogeneic HCT: safety and feasibility results Blood 2000 96: 586a
Sokos DR, Berger M, Lazarus HM . Intravenous immunoglobulin (IVIG): appropriate indications and uses in hematopoietic stem cell transplantation Biol Blood Marrow Transplant (in press)
Quinnan GV, Kirmani N, Rook AH et al. Cytotoxic T-cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus in bone marrow recipients New Engl J Med 1982 307: 7 13
Reusser P, Riddell SR, Meyers JD et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease Blood 1991 78: 1373 1380
Ljungman P, Aschan J, Azinge JN et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation Br J Haematol 1993 83: 118 124
Krause H, Hebart H, Jahn G . Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease Bone Marrow Transplant 1997 19: 1111 1116
Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation Blood 2001 97: 1232 1240
Gratama JW, Van Esser JW, Lamers CH et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection Blood 2001 98: 1358 1364
Boland GN, Vlieger AM, Ververs C et al. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation Clin Exp Immunol 1992 88: 506 511
Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor New Engl J Med 1995 334: 1038 1044
Sun Q, Pollock KE, Burton RL et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein–Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65 Blood 1999 94: 3242 3250
Einsele H, Rufer E, Roosnek E et al. T-cell therapy for chemotherapy-refractory CMV infection Blood 2000 96: 478a
La Rosa C, Krishnan R, Markel S et al. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries Blood 2001 97: 1776 1786
Acknowledgements
The author expresses gratitude to Ms Suzanne Kelly for the preparation of this manuscript. The author is supported in this work by grants CA30206 and M01 RR-43 from the National Institutes of Health.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zaia, J. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant 29, 633–638 (2002). https://doi.org/10.1038/sj.bmt.1703407
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703407
Keywords
This article is cited by
-
Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT
Bone Marrow Transplantation (2014)
-
Cytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies
Indian Pediatrics (2013)
-
Molecular Diagnosis and Management of Viral Infections in Hematopoietic Stem Cell Transplant Recipients
Molecular Diagnosis & Therapy (2012)
-
Pulmonale Infektionen in der pädiatrischen Hämatologie und Onkologie
Monatsschrift Kinderheilkunde (2011)
-
Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2006)